BAMM (BRAF Autophagy and MEK Inhibition in Melanoma): A Phase I/II Trial of Dabrafenib, Trametinib, and Hydroxychloroquine in Advanced <i>BRAFV600</i>-mutant Melanoma
Distribution of the number of citations over years.